# Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer risk? A meta-analysis

## TL;DR

This study investigates whether two genetic variations, TP53 Arg72Pro and MDM2 T309G, are linked to an increased risk of bladder cancer.

## Contribution

The study provides a meta-analysis of these polymorphisms and identifies a significant association in the Turkish population.

## Key findings

- No overall significant association was found between the polymorphisms and bladder cancer risk.
- In the Turkish population, the MDM2 T309G polymorphism showed a significant association with increased bladder cancer risk.
- Sensitivity analysis revealed multiple significant associations between the polymorphisms and bladder cancer occurrence.

## Abstract

We still do not know the exact cause of bladder cancer (BC).

Evaluation of the effect of TP53 Arg72Pro and MDM2 T309G polymorphisms with the risk of Bladder cancer.

A literature search was conducted followed by a meta-analysis. Then, sensitivity and subgroup analyses were performed. 14 relevant studies were included in the quantitative analysis.

No statistically significant associations were found. The results of the subgroup analysis revealed a significant association in the Turkish population for T309G: G vs. T (P-value= 0.015; OR 95%CI= 1.51 [1.084; 2.125]), GG vs.TT (P-value= 0.009; OR 95% CI= 2.60 [1.262; 5.370]). Sensitivity analysis revealed a significant association between the Arg72Pro: C vs. G (OR= 1.22, 95% CI [1.05; 1.40]), CC vs. GG (OR= 1.54; 95% CI [1.13; 2.09]), CC+CG vs. GG (OR= 1.24; 95% CI [1.01; 1.53]), CC vs. CG+GG (OR= 1.33; 95% CI [1.01; 1.74]), and T309G: G vs. T (OR= 1.30; 95% CI [1.07; 1.57]), GG vs. GT+TT (OR= 1.53; 95% CI [1.10; 2.11]), GG vs. GT (OR=1.44; 95% CI [1.02; 2.02]), GG vs. TT (OR= 1.88; 95% CI [1.25; 2.82]) with BC occurrence.

The T309G polymorphism was found to be a predisposing allele for BC in Turkish population.